YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
It has been about a month since the last earnings report for NeuroPace, Inc. (NPCE). Shares have lost about 0.4% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release…
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, favorable RNS reimbursement, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indicati…
NeuroPace, Inc. NPCE has hit a regulatory delay in its bid to expand the RNS System into idiopathic generalized epilepsy, or IGE. The FDA's July 2026 response pushes out a potential growth catalyst beyond the company's established focal ep…
NeuroPace, Inc. NPCE is showing better operating momentum as RNS System adoption expands and losses narrow. Second-quarter results supported the growth case, while a broader commercial reach and new technology tools could deepen utilizatio…
NeuroPace, Inc. NPCE shares have declined 12.7% in the past three months even as the company's core responsive neurostimulation, or RNS, franchise has continued to strengthen. The pullback leaves investors weighing improving focal-epilepsy…
NeuroPace, Inc. NPCE reported a second-quarter 2026 loss per share of 18 cents, compared with a loss of 30 cents in the year-ago period. The figure beat the Zacks Consensus Estimate by 5.3%. Shares of NPCE were down approximately 2.3% duri…
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indication offers a long-term growth…
NeuroPace, Inc. (NASDAQ:NPCE) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first "AI-driven clini…
It has been about a month since the last earnings report for NeuroPace, Inc. (NPCE). Shares have lost about 0.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue lea…
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indication offers a long-term growth…
NeuroPace NPCE recently announced that the FDA has approved its ECoG Assistant, its first AI-driven feature to assist clinicians in epilepsy care. With this approval, the company takes a step forward in its AI platform strategy, applying i…
NeuroPace, Inc. NPCE is moving through a clean strategic reset in 2026. The company is exiting the DIXI Medical distribution business and leaning fully into its core responsive neurostimulation franchise, where reimbursement and pricing ac…
NeuroPace, Inc. NPCE is tightening its focus around one thing: the RNS System, a closed-loop implant built for drug-resistant epilepsy. The setup is designed to generate recurring procedure-driven revenues, supported by reimbursement tailw…
NeuroPace, Inc. NPCE is tightening its focus on the core RNS franchise as it exits the DIXI distribution and leans into workflow upgrades designed to expand clinician capacity. The company is positioning software, not just hardware, as the…
NeuroPace NPCE delivered a first-quarter 2026 adjusted loss per share of 13 cents compared with an adjusted loss of 18 cents in the year-ago period. The figure was 31.6% narrower than the Zacks Consensus Estimate. GAAP loss per share for t…
Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership throug…
NeuroPace, Inc. NPCE shares soared 6.3% in the last trading session to close at $18.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.4% gain over the past…
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indication offers a long-term growth…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. NeuroPace is back on investor radar as analysts update their models and lift the fair value price t…
NeuroPace, Inc. NPCE enters 2026 after posting $100 million in 2025 revenue, up 25% year over year. The business is also moving toward a cleaner mix, with the core RNS System taking center stage as non-core revenue rolls off. The company i…
NeuroPace, Inc. NPCE is building a procedure-driven growth story around its RNS System, a brain-responsive implant designed to reduce seizures in adults with drug-resistant focal epilepsy. The company exited 2025 with stronger sales, expan…
NeuroPace, Inc. NPCE is moving beyond a device-only story and leaning into software and workflow tools that aim to expand clinician capacity. The company is also pursuing an indication expansion that could broaden the eligible patient pool…
Medical device company NeuroPace(NASDAQ: NPCE) was showing signs of life on the stock market Wednesday. In late-session trading, the company's shares were slightly in positive territory with a nearly 1% rise. This was largely a reaction to…
Key Points The niche medical devices specialist published its latest quarterly and annual fundamentals. Led by its No. 1 product, it posted a double-digit revenue gain and narrowed its net loss in the fourth quarter.10 stocks we like bette…
Earnings Call Insights: NeuroPace (NPCE) Q4 2025 MANAGEMENT VIEW * Joel Becker, CEO, reported "strong quarterly revenue of $26.6 million, representing 24% year-over-year growth" and highlighted that RNS System revenue reached "$22.4 millio…
Image source: The Motley Fool. Date Tuesday, March 3, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Joel Becker Chief Financial Officer — Patrick Williams Need a quote from a Motley Fool analyst? Email pr@fool.com Full C…
NeuroPace logo Key Points NeuroPace reported Q4 revenue of $26.6M (up 24% YoY) and full-year 2025 revenue of $100M, driven by RNS System sales (RNS up 26% in Q4 and 25% for the year), with adjusted EBITDA positive $0.9M—the second consecut…
LivaNova (LIVN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items. This…
Wall Street expects a year-over-year increase in earnings on higher revenues when NeuroPace, Inc. (NPCE) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's e…
In the current U.S. market landscape, major stock indexes have recently experienced fluctuations, with notable gains following Nvidia's impressive earnings results and Walmart's strong performance. Amidst these developments, investors may…
Image source: The Motley Fool. Date Tuesday, Nov. 4, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Joel BeckerChief Financial Officer — Patrick Williams Need a quote from a Motley Fool analyst? Email pr@fool.com Takeaway…
(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as…
Earnings Call Insights: NeuroPace (NPCE) Q3 2025 MANAGEMENT VIEW * CEO Joel Becker stated the third quarter delivered record results for NeuroPace, with total revenue reaching $27.4 million, representing 30% year-over-year growth. Becker i…
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This…
As the U.S. stock market experiences a pullback with major indices like the Dow Jones, Nasdaq, and S&P 500 showing declines, investors are increasingly cautious amid mixed earnings reports and fluctuating tech shares. In such an environmen…
As the U.S. stock market navigates a mixed landscape, with the Nasdaq gaining momentum from tech deals and the Dow facing headwinds, investors are keenly focused on earnings reports and employment data amid a prolonged government shutdown.…